3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now

The renowned provider of POCs has a market capitalization of $212.4 million. The company projects 50.2% growth for 2024 and expects to witness continued improvements in its business. Inogen's P/S ratio of 0.7X compares favorably with the industry's 3.1X. Downsides The Zacks Consensus Estimate for second-quarter 2024 revenues is pegged at $82.3 million, suggesting a 1.6% decline from the year-ago reported number. DexCom, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22.9%. DX ...